HeartBeam, Inc. (BEAT) - 10-K Summary
Business Context and Reporting Period
Company: HeartBeam, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: HeartBeam is a medical technology company developing ambulatory cardiac monitoring solutions. Its core product, the HeartBeam System, is a cable-free, credit-card-sized device that captures 3D ECG signals to synthesize a 12-Lead ECG for arrhythmia assessment. The company received FDA clearance for its 3D ECG technology in December 2024 and for its 12-Lead synthesis software in December 2025. As of December 31, 2025, the company had 16 employees and generated no revenue.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(21,015) | $(19,448) |
| Operating Expenses | $21,139 | $19,887 |
| Cash and Cash Equivalents (Year End) | $4,380 | $2,377 |
| Net Cash Used in Operating Activities | $(13,988) | $(14,471) |
| Net Cash Provided by Financing Activities | $16,591 | $866 |
| Total Assets | $5,843 | $3,276 |
| Total Liabilities | $3,240 | $1,622 |
Note: The filing text does not provide specific gross margin or debt figures as the company has no revenue and no long-term debt listed in the balance sheet summary.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by $1.6 million (8%) to $21.0 million, driven primarily by a $2.4 million (22%) increase in Research and Development (R&D) expenses.
- R&D Expenses: Increased due to higher product development costs ($1.5M), headcount reallocation to AI and R&D ($1.2M), and increased stock-based compensation ($1.4M). These were partially offset by lower clinical study costs ($0.7M) and consulting expenses ($1.0M).
- G&A Expenses: Decreased by $1.1 million (13%) due to lower stock-based compensation ($0.6M), reduced consulting costs ($0.4M), and lower employee costs ($0.3M).
- Liquidity: Cash and cash equivalents increased by $2.0 million to $4.4 million, primarily due to $16.6 million in net proceeds from equity sales (including an At-The-Market offering and a public offering).
- Stock-Based Compensation: Total stock-based compensation expense increased to $5.1 million in 2025 from $4.3 million in 2024.
Guidance, Outlook, and Risks
Outlook and Strategy:
- Commercial Launch: The company plans a limited market introduction in early 2026 targeting concierge and preventive cardiology groups.
- Product Pipeline: Pursuing FDA indication expansion for heart attack detection and developing an extended-wear 12L ECG patch prototype.
- AI Integration: Leveraging longitudinal data to build AI-based screening and prediction algorithms.
- Recent Milestones (Post-Year End): Announced ClearCardio as the first commercial customer (March 2026), enrolled first patients in the ALIGN-ACS heart attack detection study (March 2026), and entered a strategic AI collaboration with Mount Sinai (March 2026).
Risks and Contingencies:
- Going Concern: Management and auditors have expressed substantial doubt about the company's ability to continue as a going concern. Existing cash ($4.4M) is deemed insufficient to fund operations for the next 12 months without additional financing.
- Capital Needs: The company requires additional capital to support growth, commercialization, and R&D. Failure to secure funding could force curtailment of operations.
- Regulatory: Future product modifications or new indications (e.g., heart attack detection) require additional FDA clearances, which are not guaranteed and could be delayed.
- Reimbursement: Revenue depends on third-party payer reimbursement, which is uncertain for new technologies and may be classified as "experimental."
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $4.4 million cash balance against the projected burn rate and the timeline for the early 2026 commercial launch.
- Financing Status: Confirm the status of the At-The-Market (ATM) offering (approx. $8.1M remaining capacity as of March 2026) and any new equity/debt financing secured post-filing.
- Commercial Traction: Monitor the conversion of the Letter of Intent (LOI) with ClearCardio into a definitive agreement and the revenue recognition timeline.
- Regulatory Progress: Track the enrollment and results of the ALIGN-ACS study for heart attack detection indication expansion.
- Stock-Based Compensation: Review the impact of milestone-based vesting (triggered by FDA clearance) on future expense recognition.